Immunohistochemical expression of CD56 in dog (Canis familiaris) odontogenesis

Nel, Sulette; Heerden, Marlene van; Heerden, W.F.P. Van

doi:10.1016/j.archoralbio.2015.08.002

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,20,21,30 There are commercially available antibodies for CD56 and CD30 that cross-react with the canine formalinfixed antigens. [18][19]23 Both NK cells and NK-like T cells express CD56, the latter of which also express T-cell markers such as CD3. CD30 is a cell surface receptor that is highly expressed on recently activated gd T cells in humans, as well as on normal activated T and B lymphocytes.…”

Section: Discussionmentioning

confidence: 99%

“…Immunohistochemistry using polyclonal rabbit anti-human CD3 (DAKO, 1:200), polyclonal rabbit anti-human CD20 (Thermo/Neomarkers, 1:200), and monoclonal mouse anti-human CD56 (BC56C04, BioCare, 1:100) was performed on a Bond-Max automated system (Leica Microsystems, Bannockburn, IL) using a biotin-free, polymeric peroxidase-based detection kit with DAB chromagen and hematoxylin counterstain (Bond Polymer Refine Detection kit; Leica Microsystems) as previously described. 4,18,23 Immunohistochemistry for monoclonal mouse anti-human CD30 (Ber-H2, DAKO, 1:50) was performed on a DAKO 48 immunostainer using a biotin-free, polymeric peroxidase-based detection kit with DAB chromagen and hematoxylin counterstain (FLEX Detection kit; DAKO). 19 Antigen retrieval was achieved by incubating slides in low pH retrieval solution (CD30) for 20 minutes on the Dako PT link or in Bond Epitope Retrieval Solution I (CD3 and CD20) or Bond Epitope Retrieval Solution 2 (CD56) for 20 minutes on the Bond-Max automated system.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Subcutaneous Panniculitis-Like T-cell Lymphoma in Dogs: Morphologic and Immunohistochemical Classification

2018

View full text Add to dashboard Cite

Canine nonepitheliotropic cutaneous T-cell lymphomas (NECTCL) are poorly characterized. In humans, a number of distinct subtypes of NECTCL have been recognized, including subcutaneous panniculitis-like T-cell lymphoma (SPTCL). Five dogs with subcutaneous T-cell lymphomas histologically similar to SPTCL in humans are herein described. The mean age was 8.5 years (5.5 to 12 years). No breed or sex predilection was identified in this small cohort. Two dogs presented with an acute onset of multiple skin masses and 3 dogs had solitary masses with subsequent development of multiple smaller masses within 0.5 to 2 months post-diagnosis without treatment. Locations, when specified, included shoulder, neck, and ventral abdomen. Two dogs were euthanized following diagnosis and one dog treated with chemotherapy (CCNU) survived 7 months post-diagnosis. Histologically, all cases were characterized by proliferations of either small to intermediate or large sized, CD3-positive T cells that infiltrated the subcutis in a lace-like pattern and frequently rimmed adipocytes. No epitheliotropism was observed, neoplastic cells were often karyorrhectic, and there were regions of extensive necrosis. Heavy infiltrates of histiocytes with prominent phagocytosis masked the lymphoid neoplastic cell population in some sections. A clonal T-cell receptor gamma gene rearrangement was found in 4 of the 5 cases. While SPTCLs typically have a less aggressive clinical course in humans, their biological behavior in dogs remains to be determined. In summary, SPTCL may represent a distinct entity in dogs and needs to be accurately diagnosed to better determine clinical behavior.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Subcutaneous Panniculitis-Like T-cell Lymphoma in Dogs: Morphologic and Immunohistochemical Classification

2018

View full text Add to dashboard Cite

show abstract

Proteomic analysis of canine oral tumor tissues using MALDI-TOF mass spectrometry and in-gel digestion coupled with mass spectrometry (GeLC MS/MS) approaches

et al. 2018

View full text Add to dashboard Cite

Oral tumors, including highly invasive and metastatic oral melanoma (OM), non-tonsillar oral squamous cell carcinoma (OSCC) and benign tumors (BN), are common neoplasms in dogs. Although these tumors behave differently, limited data of their protein expression profiles have been exhibited, particularly at the proteome level. The present study aimed to i.) characterize peptide-mass fingerprints (PMFs) and identify potential protein candidates of OM, OSCC, BN and normal control subjects, using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and liquid chromatography tandem mass spectrometry (LC-MS/MS), ii.) identify potential protein candidates associated with the diseases, using in-gel digestion coupled with mass spectrometric analysis (GeLC-MS/MS) and iii.) search for relationships between chemotherapy drugs and disease-perturbed proteins. A distinct cluster of each sample group and unique PMFs with identified protein candidates were revealed. The unique peptide fragment at 2,274 Da of sacsin molecular chaperone (SACS) was observed in early-stage OM whereas the fragment at 1,958 Da of sodium voltage-gated channel alpha subunit 10 (SCN10A) was presented in early- and late-stage OM. The peptide mass at 2,316 Da of Notch1 appeared in early-stage OM and benign oral tumors while the peptide mass at 2,505 Da of glutamate ionotropic receptor N-methyl-D-aspartate type subunit 3A (GRIN3A) was identified in all groups. Markedly expressed proteins from GeLC-MS/MS included Jumonji domain containing 1C (JMJD1C) in benign tumors, inversin (INVS) and rho guanine nucleotide exchange factor 28 (ARHGEF28) in OM, BTB domain-containing 16 (BTBD16) in OSCC, and protein tyrosine phosphatase non-receptor type 1 (PTPN1), BRCA2, DNA repair associated (BRCA2), WW domain binding protein 2 (WBP2), purinergic receptor P2Y1 and proteasome activator subunit 4 (PSME4) in all cancerous groups. The network connections between these proteins and chemotherapy drugs, cisplatin and doxorubicin, were also demonstrated. In conclusion, this study unveiled the unique PMFs and novel candidate protein markers of canine oral tumors.

show abstract